The effects of peroral administration of Tofogliflozin(SGLT2 inhibitor) on endogenous glucose production and insulin clearance, single effet and chronic effect. - The effect of Tofogliflozin(SGLT2 inhibitor) on endogenous glucose production and insulin clearance

niversity of Juntendo0 个研究点目标入组 12 人开始时间: 2018年3月16日最近更新: 2023年10月17日

试验速览

暂无简介。

•-type 1 diabetes mellitus -past history of taking Tofogliflozin -BMI range:>30 or <18.5 kg/m2 -liver dysfunction(AST,ALT => 51U/L,gamma-GTP over 101U/L) -renal dysfunction or eGFR level =< 60mL/min/1.73m2 -Patient with severe heart diseases (for example, heart failure and unstable angina) or the patient who occured myocardial infarction and anginal attack after 24 weeks ago from observation period -patient who had an apoplexy spasm (cerebral infarction and cerebral hemorrhage) within 24 weeks until agreement acquisition -patient with malignant tumor -patient with advanced diabetes complications (neuropathy , retinopathy and nephropathy) -patient of serious illness ketotic, a diabetic coma or the previous coma -Patient with the endocrine diseases for which treatment is insufficient for hormone replenishment method of treatment (for example,pituitary disease, thyroid disease and adrenal disease) -anemia beyond the degree of middle class (hemoglobin < 9.5g/dL) -drunkard(for example 1 daily mean sake, by 3 gou and beer, more than 3 flagons) -subjects judged unsuitable to the study from staff

发起方

niversity of Juntendo